New drug combo shows promise against advanced cervical cancer in early trial
NCT ID NCT07205497
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 24 times
Summary
This study tests whether adding the immunotherapy drug QL1706 to standard chemotherapy before surgery can improve outcomes for people with locally advanced cervical cancer. About 54 participants will receive the combination, then have surgery to remove the tumor. Researchers will measure how many have no cancer left after treatment and track side effects. The goal is to see if this approach is more effective than chemotherapy alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Sun Yat-sen Memorial Hospital of the Sun Yat-sen University
Guangzhou, Guangdong, 537216, China
Conditions
Explore the condition pages connected to this study.